The European Patients’ Academy (EUPATI) is a pan-European Innovative Medicines Initiation focusing on education and training.


The European Patients’ Academy (EUPATI) (This link will take you away from our website)  is a pan-European Innovative Medicines Initiative project of 33 organizations, led by the European Patients’ Forum, with partners from patient organizations (The ALLIANCE, the European Genetic Alliance, the European AIDS Treatment Group, and EURORDIS), universities and not-for-profit organisations, along with a number of pharmaceutical companies.

They focus on education and training to increase the capacity and capability of patients to understand and contribute to medicines research and development and also improve the availability of objective, reliable, patient-friendly information for the public.

EUPATI launched the Patient Expert Training Course in October 2014 in English and had 20 UK EUPATI Fellows graduate in December 2016. The third round of the EUPATI Patient Expert Training Courses (This link will take you away from our website) have been announced for 2017-2018.

These courses do not educate about disease-specific issues or therapies, but about the process of medicines development in general. Indication-specific information or specific medicine interventions are beyond the scope of European Patients’ Academy and are the remit of health professionals as well as patient organisations.

The Health and Social Care Alliance Scotland (The ALLIANCE) chairs the EUPATI UK National Liaison Team (This link will take you away from our website), made up of academic representative Dr Sue Pavitt, Industry representative Kay Warner, working alongside the newly graduated Fellows. The UK National Liaison Team aims to raise the profile of EUPATI on a country level, form a national network of stakeholders who can help disseminate information about EUPATI’s education and information resources, and generate a dialogue around future patient involvement in the medicines research and development process in the UK.